Shenzhen Hepalink Pharmaceutical Group (002399.SZ): Enoxaparin Sodium Injection Obtains Drug Registration Approval in Argentina.

Shenzhen Hepalink Pharmaceutical Group (002399.SZ) announced that its wholly-owned subsidiary, Shenzhen TianDao Pharmaceutical Co., Ltd. (referred to as "TianDao Pharmaceutical"), recently received approval notice for its enoxaparin sodium injection from the National Administration of Drugs, Food, and Medical Devices of Argentina (ANMAT). The announcement states that enoxaparin sodium injection is indicated for: prevention of venous thromboembolic disease caused by moderate to high-risk surgical procedures, especially in patients undergoing orthopedic or general surgery (including cancer surgery); prevention of venous thromboembolic disease in patients with acute diseases (such as acute heart failure, respiratory failure, severe infection, or rheumatic diseases) that limit mobility and increase the risk of thromboembolism; treatment of deep vein thrombosis and pulmonary embolism, excluding the need for thrombolytic therapy or surgery for pulmonary embolism; long-term treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism in patients with active cancer; prevention of thrombus formation during extracorporeal circulation in hemodialysis; treatment of acute coronary syndrome: in combination with aspirin, for the treatment of unstable angina and non-ST-segment elevation myocardial infarction; treatment of acute ST-segment elevation myocardial infarction, including patients requiring medical treatment or percutaneous coronary intervention (PCI).